Patents Examined by Padmashri Ponnaluri
-
Patent number: RE48137Abstract: Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment and prevention of Staphylococcus aureus infections in a subject.Type: GrantFiled: February 23, 2018Date of Patent: August 4, 2020Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Mark Shirtliff, Janette Harro, Jeffrey Leid
-
Patent number: RE48389Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: GrantFiled: September 6, 2017Date of Patent: January 12, 2021Assignees: AGENSYS, INC., SEAGEN INC.Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
-
Patent number: RE48404Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.Type: GrantFiled: July 5, 2017Date of Patent: January 26, 2021Assignee: Helixmith Co., LtdInventors: Jong-Mook Kim, Woong Hahn, Eun-Jin Park
-
Patent number: RE48468Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.Type: GrantFiled: January 26, 2018Date of Patent: March 16, 2021Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis LeidenInventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
-
Patent number: RE48558Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.Type: GrantFiled: February 28, 2018Date of Patent: May 18, 2021Assignee: GENENTECH, INC.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: RE48652Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.Type: GrantFiled: May 14, 2018Date of Patent: July 20, 2021Assignee: BIONEER CORPORATIONInventors: Ji Hee Kang, Byeung Il You, Sung Il Yun, Han Oh Park
-
Patent number: RE48805Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (AAD) fusion protein for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, binds to human serum albumin (HSA) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. The AAD fusion protein can also be used as a component for detection and quantitative analysis of arginine in a testing kit for various samples including blood, food and analytical samples.Type: GrantFiled: February 12, 2019Date of Patent: November 2, 2021Assignee: Vision Global Holdings Ltd.Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung
-
Patent number: RE48960Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.Type: GrantFiled: December 19, 2019Date of Patent: March 8, 2022Assignee: The University of Western AustraliaInventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
-
Patent number: RE49251Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: March 26, 2021Date of Patent: October 18, 2022Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Patent number: RE49339Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.Type: GrantFiled: April 10, 2019Date of Patent: December 20, 2022Assignees: The Regents of The University of Colorado, A Body Corporate, MUSC Foundation For Research DevelopmentInventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik, Stephen Tomlinson
-
Patent number: RE49340Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.Type: GrantFiled: May 2, 2019Date of Patent: December 20, 2022Assignees: National Taiwan University, National Yang Ming Chiao Tung University, National Health Research InstitutesInventors: Yufeng Jane Tseng, Yu-Li Liu, Chung-Ming Sun, Hai-Gwo Hwu, Chih-Min Liu, Wen-Sung Lai
-
Patent number: RE49347Abstract: The invention provides vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising (a) at least one expression cassette (POI) for expressing a polypeptide of interest; (b) an expression cassette (MSM) comprising a mammalian selectable marker gene; (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene; wherein the expression cassette (POI) is flanked 5? by the expression cassette (MASM), the expression cassette (MSM) is located 3? from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5? to 3? orientation. Also provided are host cells, comprising said vector and methods for producing a polypeptide using respective host cells.Type: GrantFiled: August 23, 2018Date of Patent: December 27, 2022Assignee: Novartis AGInventors: Hans-Peter Knopf, Burkhard Wilms
-
Patent number: RE49431Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-? using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2?-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.Type: GrantFiled: August 11, 2020Date of Patent: February 28, 2023Assignee: NITTO DENKO CORPORATIONInventors: Kenjirou Minomi, Hirokazu Takahashi, Erika Terada, Jens Harborth, Jun Zhang, Mohammad Ahmadian, Wenbin Ying
-
Patent number: RE49435Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: GrantFiled: January 29, 2020Date of Patent: February 28, 2023Assignee: Seagen Inc.Inventors: Julie DeSander, Jeffrey Behrens
-
Patent number: RE49495Abstract: The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55). The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55), and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.Type: GrantFiled: April 6, 2020Date of Patent: April 18, 2023Assignee: AFFIBODY ABInventors: Erik Nordling, Joakim Nilsson, Patrik Strömberg
-
Patent number: RE49583Abstract: Provided is an rtTA and single chain rtTA variants and uses thereof for inducible expression of a nucleic acid of interest. Nucleic acid molecules comprising an improved rtTA and/or sc rtTA sequence according to the invention are also provided, as well as vectors, replicons and cells comprising such nucleic acid molecules.Type: GrantFiled: February 3, 2021Date of Patent: July 18, 2023Assignee: TET Systems GmbH & Co. KGInventors: Benjamin Berkhout, Atze T. Das
-
Patent number: RE49625Abstract: The present invention provides devices and methods to separate and concentrate target protein species at a microliter scale and to generate reagents to those variants with exquisite selectivity for specific protein isoforms using only picograms of target material.Type: GrantFiled: April 10, 2020Date of Patent: August 29, 2023Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONAInventors: Michael Sierks, Mark Hayes
-
Patent number: RE49708Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: GrantFiled: January 8, 2021Date of Patent: October 24, 2023Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCHInventors: George C. Prendergast, Richard Metz
-
Patent number: RE49736Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: GrantFiled: March 18, 2020Date of Patent: November 28, 2023Assignee: Jazz Pharmaceuticals II SASInventor: Thierry Abribat
-
Patent number: RE49908Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: June 30, 2021Date of Patent: April 9, 2024Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst